Understanding the neurotoxicity effects of CAR-T cell therapy
Official title: Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy
Funded at Sloan-Kettering Inst Can Research · NIH-10945877 · Data updated 2026-11-12
This study is looking at the brain-related side effects that some people might experience after receiving CAR-T cell therapy, especially a condition called ICANS, to better understand how it affects thinking and memory over time, so we can help patients feel better and manage their care more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 15, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $610,197 |
| NIH project number | 1R01CA293922-01 |
| Project ID | NIH-10945877 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are receiving CAR-T cell therapy for hematologic malignancies.
✕Less likely to help
Patients who are not undergoing CAR-T cell therapy or those with pre-existing severe neurological conditions may not benefit from this research.
What this research studies
This research investigates the neurological side effects associated with CAR-T cell therapy, particularly focusing on a condition known as immune effector cell-associated neurotoxicity syndrome (ICANS). The study aims to characterize both acute and chronic neurological symptoms that may arise in patients receiving this treatment. By analyzing blood markers and conducting neurocognitive assessments, researchers hope to uncover the underlying mechanisms of these toxicities and their long-term impacts on patients' cognitive functions. This work is crucial for improving patient management and outcomes following CAR-T therapy.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of neurotoxicity in patients undergoing CAR-T cell therapy, potentially improving their quality of life.
How similar studies have gone: While CAR-T therapy has shown remarkable efficacy in treating certain cancers, the specific investigation of neurotoxicity and its chronic effects is still an emerging area of research.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Santomasso, Bianca Denise — Sloan-Kettering Inst Can Research
- Study coordinator: Santomasso, Bianca Denise
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.